An observational,cohort study to compare the efficacy of Fingolimod to injectable disease modifying therapies in patients with relapse remitting Multiple Sclerosis
Latest Information Update: 07 Feb 2019
Price :
$35 *
At a glance
- Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Interferon (Primary) ; Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 27 Apr 2018 Results (n= approx 25000) assessing propensity score matched comparative effectiveness analysis of dimethyl fumarate relative to interferon, glatiramer acetate, or teriflunomide treated RRMS outpatients in the german neurotransdata registry, were presented at the 70th Annual Meeting of the American Academy of Neurology.
- 27 Apr 2018 Results (n= approx 25000) assessing effectiveness analysis of dimethyl fumarate relative to fingolimod-treated RRMS outpatients in the german neurotransdata registry, were presented at the 70th annual meeting of the american academy of neurology.
- 28 Oct 2017 Results (n= approx 25000) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.